$MSAI Cashflow Statement | Understand Stock

$MSAI

$3.40 -$0.20 (5.56%) Close

$MSAI Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 8 months to Dec 31, 2021
Operating Activities:
Net Income Loss
Net loss
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Interest earned on cash and securities held in Trust Account
Depreciation
Inventory impairment
Non-cash lease activity
Inventory casualty losses
Bad debt expenses (recoveries)
Deferred income tax (income) expense
Share-based compensation
Non-cash PIK interest
Loss (gain) on disposal of equipment
Loss on financing transaction
Change in fair value of warrants liabilities
Other income (expense), net
Change in fair value of convertible notes

Increase (decrease) in cash resulting from changes in:
Prepaid expenses
Trade accounts receivable
Deferred transaction costs
Inventories
Other current assets
Other noncurrent assets
Trade accounts payable
Income taxes payable
Deferred tax liability
Franchise taxes payable
Due to related party
Income taxes receivable
Contract liabilities
Other current liabilities
Right of use liabilities
Accrued expenses
Due from related party
Other liabilities
Contract liabilities, noncurrent

Net cash provided by (used in) operating activities
Investing Activities:
Principal deposited in Trust Account
Cash withdrawn from Trust Account to pay taxes
Capital expenditures
Proceeds from sale of equipment
Net cash provided by (used in) investing activities

Financing Activities:
Proceeds from initial public offering, net of costs
Proceeds from sale of founder shares
Proceeds from private placement units
Payment of promissory note - related party
Payment of deferred offering costs
Equity Line of Credit
Total payment of deferred offering costs

Proceeds from lines of credit
First Insurance Funding
Wells Fargo
B1 Bank
Total proceeds from lines of credit

Proceeds from issuances of common stock and Pre-funded warrants
Repayments of promissory notes
Nonrelated Party
Total repayments of promissory notes
Proceeds from issuance of common stock
Equity Line of Credit
Total proceeds from issuance of common stock
Proceeds from Equity Line of Credit issuances
Merger recapitalization
Tax payments associated with equity-based compensation transactions
Repayments of lines of credit
First Insurance Funding
Wells Fargo
B1 Bank
Total repayments of lines of credit

Proceeds from promissory notes
Related party
Legacy SMAP
Proceeds from shareholder promissory notes
Repayments on shareholder promissory notes
Proceeds from convertible notes
Proceeds from financing transaction
Proceeds from promissory notes
Net cash provided by (used in) financing activities

Net increase/(decrease) in cash, cash equivalents, and restricted cash equivalents
Cash, cash equivalents, and restricted cash equivalents beginning of period
Cash, cash equivalents, and restricted cash equivalents end of the period
Deferred offering costs paid by related party
Remeasurement of common stock subject to possible redemption
Supplemental cash flow information:
Interest paid
Income tax paid, net of refunds received
Non-cash investing and financing activities:
Conversion of promissory notes
Settlement of vendor liability with share issuance
Sale of equipment
Conversion of convertible notes
Conversion of related party promissory note into convertible notes
Conversion of Legacy SMAP promissory loan into common stock
Legacy SMAP
Total conversion of Legacy SMAP promissory loan into common stock
Shares issued for Equity Line of Credit commitment fee
Inducement shares from Financing Transaction
Reconciliation of cash, cash equivalents and restricted cash equivalents at end of period:
Cash and cash equivalents
Restricted cash equivalents included in other current assets

Comments